A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris

Inclusion Criteria:

- Non-pregnant female subjects ≥ 12 years of age with facial acne vulgaris

- Subjects with an Investigator's Global Assessment (IGA) of Inflammatory Lesions of
Acne Vulgaris of Moderate (3) or Severe (4) at Baseline.

- Subjects with ≥ 30 facial inflammatory lesions

Exclusion Criteria:

- Subjects with < 10 or > 75 facial non-inflammatory lesions

- Subjects with > 3 facial nodular or cystic lesions at Baseline

- Standard exclusion criteria